List of Contributors.
Preface.
Preface from Prostaglandins.
Acknowledgements.
Foreword.
Section One: Biosynthesis and Metabolism
1. Perspectives on the Biosynthesis and Metabolism of
Eicosanoids (Robert C. Murphy, Rebecca C. Bowers, Jennifer
Dickinson and Karin Zemski-Berry).
2. Control of Eicosanoid Production by Cellular and Secreted
Phospholipase A2 (Marise Andreani, Jean-Luc Olivier and
Gilbert Bereziat).
3. Mechanisms of PGH synthase-1 (COX-1) activity and role of
radical states (Carol Deby and Ginette Deby-Dupont ).
4. Regulation and Function of Prostaglandin Synthase
2/Cyclooxygenase II (Harvey R. Herschman).
5. Mammalian Lipoxygenases (Shozo Yamamoto, Hiroshi
Suzuki, Natsuo Ueda, Yoshitaka Takahashi and Tanihiro
Yoshimoto).
6. Biosynthesis and Biological Effects of 5-oxo-ETE and other
Oxoeicosatetraenoic Acids (William S. Powell).
7. Synthetic Eicosanoids (Norrie. H. Wilson).
Section Two: Analytic al Methods
8. Perspectives of Analytical Methods for Eicosanoids (Jay
Y. Westcott and Angelo Sala).
9. Enzyme Immunoassays of Metabolites and Enzymes Using
Acetylcholinesterase as label (Christophe Creminon and Jacques
Maclouf).
10.Bioassay of Eicosanoids (Robert L. Jones).
11. Gas Chromatography and Mass Spectometry in Eicosanoid
Analysis (Michinao Mizugaki, Takanori Hishinuma, Naoto Suzuki).
12. Time-resolved Fluoroimmunoassay in Eicosanoid Analysis
(Werner Schlegel and Harald John).
Section Three: Biochemical and Molecular Pharmacology
13. Perspectives and Clinical Significance of the Biochemical
and Molecular Pharmacology of Eicosanoids (Subhash P.
Khanapure and L. Gordon Letts).
14. Eicosanoid Antagonists (Kiyoshi Yasui and Akinori
Arimura).
15. Biosynthesis and Degredation of Anandamide, an Endogenous
Ligand of Cannabinoid Receptors (Natsuo Ueda and Dale G.
Deutsch).
16. Inhibitors of Eicosanoids (K. D. Rainsford).
17. Biology and Chemistry of Products of the Isoprostane Pathway
(L. Jackson Roberts, II, and Jason D. Morrow).
18. Insight into Prostanoid Functions; lessons from
receptor-knockout mice (Yukihiko Sugimoto, Shuh Narumiya and
Atsushi Ichikawa).
Section Four: Immunology, Endocrinology and Metabolic
Regulation
19. Perspectives and Clinical Significance of Eicosanoids in
Immunology, Endocrinology and Metabolic Regulation (Milan R.
Henzl).
20. Prostaglandins and the Immune Response (Diana C. Fleming and
Rodney W. Kelly).
21. Leukotrienes in Aspirin-intolerant Asthma (Anthony P.
Sampson and Stephen T. Holgate).
22. Essential Fatty Acids (Yoeju Min and Michael A.
Crawford).
23. Endothelial Secretory Function and Atherothrombosis (Stefan
Chlopicki and Richard J. Gryglewski).
24. Molecular Regulation of Pancreatic Islet Prostaglandin
Sythesis and Its Relevance to Diabetes Mellitus (R. Paul
Robertson).
25. Prostaglandins, Leukotrienes and Bone (Carol C. Pilbeam and
Lawrence G. Raisz).
26. Aging and Prostaglandins (A. Hornych).
Section Five: Inflammation
27. Perspectives and Clinical Significance of Eicosanoids in
Pain and Inflammation (Burkhard Hinz and Kay Brune).
28. Anti-Inflammatory Steroids (Françoise Russo-Marie).
29. Eicosanoids and Algesia in Inflammation (Lynne Murray, Henry
Sarau and Kristen E. Belmonte).
30. Cyclooxygenase-2 in Cancer (Ovidiu C. Trifan and Jaime L.
Masferrer).
31. Cytokines and Eicosanoids in Arthritis (K. D.
Rainsford).
Section Six: Circulatory Systems
32. Prespectives and Clinical Significance of Eicosanoids in the
Circulatory System (James B. Lee).
33. Aspirin and Activated Platelets (Artur-Aron Weber).
34. Generation of Vasoactive Prostanoids by the Cyclooxygenase-2
Pathway in the Cardiovascular System of the Rat (P. J. Kadowitz, S.
R. Baber, M. M. Mazim, M. Keebler, H. C. Champion, T. J.
Bivalacqua, D. B. McNamara and A. L. Hyman).
35. Eicosanoid Generation and Effects in Cardiac Muscle and
Coronary Vessels (Karsten Schror).
Section Seven: Digestive System
36. Perspective and Clinical Significance of Eicosanoids in the
Digestive System (Chi Hin Cho, Joshua Ka Shun Ko and Marcel Wing
Leung Koo).
37. Eicosanoids and Liver Regeneration (David A. Rudnick and
Louis J. Muglia).
38. Eicosanoids and the Intestine (Klaus Bukhave and Jorgen
Rask-Madsen).
39. Eicosanoids and Stomach Physiology (Brigitta M. Peskar).
Section Eight: Nervous System
40. Perspectives and Clinical Significance of Arachidonic Acid
Release, Action and Metabolism In the Nervous System (Christopher
D. Breder).
41. Eicosanoid Pathways in the Aging of the Central Nervous
System (Hari Manev and Tolga Uz).
42. Arachidonate Metabolites in the Neurophysiological System:
The Fever Pathway (Ji Zhang and Serge Rivest).
43. Prostanoids in Pain (Tony L. Yaksh, Patrick W. Mantyh and
Camilla I. Svensson).
44. Eicosanoids: Roles in the Pathophysiology of Cerebral
Ischemia (Robert W. Hickey and Steven H. Graham).
45. NSAIDs in the Treatment of Alzheimer?s Disease (Paul
S. Aisen).
46. Prostaglandins and Eicosanoids (A.I.M. Glen and B.M.
Ross).
47. Essential Fatty Acids: Eicosanoid Precursors in the
Treatment of Huntington?s Disease (Krishna Vaddadi).
Section Nine: Conclusions and Correlations
48. Perspectives and Clinical Significance of Eicosanoids in
Obstetrics and Gynaecologic Practice (I. Z. MacKenzie).
49. Prostaglandins and Male Reproductive Physiology (Rodney W.
Kelly).
50. Prostaglandin F2: The Luteolytic Hormone (John A.
McCracken).
51. Prostaglandins in Implantation (Norman L. Poyser).
52. Parturition and the Clinical Interruption of Pregnancy (S.
Cowan and A.A. Calder).
53. Foetal and Neonatal Ductus Arteriosus (Kazuo Momma).
Section Ten: Conclusions and Correlations
54. Biochemical Interactions of Platelet-Activating Factor with
Eicosanoids (Joseph T. O?Flaherty and Robert L. Wykle).
55. Eicosanoid Precursors as Pharmaceuticals (David F.
Horrobin).
56. Pharmaceutical Exploitation: cyclooxygenase and lipoxygenase
inhibitors (Paola Patrignani and Maria G. Sciulli).
57. Pharmaceutical Exploitation: Eicosanoids and their Analogs
(David F. Woodward and June Chen).
Epilogue.
Index.
